SI2065467T1 - Protitelesa proti interferonu alfa - Google Patents
Protitelesa proti interferonu alfaInfo
- Publication number
- SI2065467T1 SI2065467T1 SI200231038T SI200231038T SI2065467T1 SI 2065467 T1 SI2065467 T1 SI 2065467T1 SI 200231038 T SI200231038 T SI 200231038T SI 200231038 T SI200231038 T SI 200231038T SI 2065467 T1 SI2065467 T1 SI 2065467T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ifn
- interferon
- alpha antibodies
- antibodies
- iddm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/56—IFN-alpha
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27077501P | 2001-02-22 | 2001-02-22 | |
US10/044,896 US7087726B2 (en) | 2001-02-22 | 2002-01-09 | Anti-interferon-α antibodies |
EP09002404.3A EP2065467B9 (en) | 2001-02-22 | 2002-01-29 | Anti-interferon-alpha antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2065467T1 true SI2065467T1 (sl) | 2014-01-31 |
Family
ID=26722123
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200230973T SI1362105T1 (sl) | 2001-02-22 | 2002-01-29 | Protitelesa proti interferonu alfa |
SI200231038T SI2065467T1 (sl) | 2001-02-22 | 2002-01-29 | Protitelesa proti interferonu alfa |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200230973T SI1362105T1 (sl) | 2001-02-22 | 2002-01-29 | Protitelesa proti interferonu alfa |
Country Status (19)
Country | Link |
---|---|
US (8) | US7087726B2 (sl) |
EP (5) | EP2301629A3 (sl) |
JP (3) | JP4384853B2 (sl) |
KR (5) | KR100940968B1 (sl) |
CN (3) | CN101857636B (sl) |
AT (1) | ATE534739T1 (sl) |
AU (3) | AU2002306432B2 (sl) |
CA (1) | CA2437161C (sl) |
CY (2) | CY1112385T1 (sl) |
DK (2) | DK2065467T5 (sl) |
ES (3) | ES2461148T3 (sl) |
HK (2) | HK1149567A1 (sl) |
IL (2) | IL157170A0 (sl) |
MX (1) | MXPA03007529A (sl) |
NZ (1) | NZ527338A (sl) |
PT (2) | PT2065467E (sl) |
RU (1) | RU2314317C2 (sl) |
SI (2) | SI1362105T1 (sl) |
WO (1) | WO2002066649A2 (sl) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4394350B2 (ja) * | 2001-01-09 | 2010-01-06 | ベイラー リサーチ インスティテュート | 対象における自己免疫疾患の治療法及びinvitro診断アッセイ |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US7638304B2 (en) * | 2001-10-05 | 2009-12-29 | Mount Sinai School Of Medicine Of New York University | Hybrid fusion protein transcription regulator to induce interferon target gene expression |
UA76638C2 (en) * | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
CA2823468A1 (en) * | 2003-04-23 | 2004-11-04 | Medarex, L.L.C. | Compositions and methods for the therapy of inflammatory bowel disease |
EP1711207B1 (en) * | 2003-12-10 | 2012-11-28 | Medarex, Inc. | Interferon alpha antibodies and their uses |
AU2012203451B2 (en) * | 2003-12-10 | 2014-06-12 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
LT2662390T (lt) * | 2004-06-21 | 2017-10-10 | E. R. Squibb & Sons, L.L.C. | Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas |
RU2007116988A (ru) * | 2004-10-07 | 2008-11-20 | Универзитет Цюрих (CH) | Применение блокаторов интерферона типа i для профилактики и лечения псориаза |
US20140154239A1 (en) * | 2012-12-05 | 2014-06-05 | Jacques Banchereau | Anti-interferon alpha monoclonal antibodies and methods for use |
RU2431638C2 (ru) * | 2005-02-10 | 2011-10-20 | Бэйлор Рисерч Инститьют | Моноклональные антитела против интерферона-альфа и способы применения |
US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
EP1893646A2 (en) * | 2005-06-22 | 2008-03-05 | Genentech, Inc. | Methods and compositions for targeting ifnar2 |
EP2476428B1 (en) | 2005-06-29 | 2013-08-21 | Yeda Research and Development Co. Ltd. | Recombinant interferon alpha 2 (IFN alpha 2) mutants |
EP2537943B1 (en) | 2006-04-24 | 2014-03-12 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
EP2057190A4 (en) * | 2006-08-09 | 2010-07-28 | Baylor Res Inst | ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE |
AU2007327993B2 (en) * | 2006-12-06 | 2013-06-20 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
JP5456658B2 (ja) * | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | 抗体製剤 |
AU2008247395A1 (en) | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Auto-antibody markers of autoimmune disease |
US20100261172A1 (en) * | 2007-05-03 | 2010-10-14 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
EP2219452B1 (en) | 2007-11-05 | 2015-10-14 | MedImmune, LLC | Methods of treating scleroderma |
CA2714410A1 (en) | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Disease markers and uses thereof |
WO2009108341A1 (en) | 2008-02-28 | 2009-09-03 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
JPWO2009116491A1 (ja) | 2008-03-21 | 2011-07-21 | 株式会社林原生物化学研究所 | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 |
US8163885B2 (en) * | 2008-05-07 | 2012-04-24 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon-alpha |
MX2012002640A (es) | 2009-09-03 | 2012-06-25 | Medimmune Llc | Diagnostico de interferon tipo 1. |
BR112013004685B1 (pt) | 2010-09-01 | 2021-09-21 | Thomas Jefferson University | Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular |
EP2701742A4 (en) * | 2011-04-26 | 2015-03-18 | Genentech Inc | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES |
KR20140043402A (ko) * | 2011-05-25 | 2014-04-09 | 메디뮨 엘엘씨 | 인터페론-알파에 대한 항체를 사용하여 전신홍반루푸스, 피부경화증 및 근육염을 치료하는 방법 |
WO2013059299A1 (en) * | 2011-10-17 | 2013-04-25 | The Uab Research Foundation | Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
CN102608328A (zh) * | 2012-03-06 | 2012-07-25 | 无锡市普生生物工程技术有限公司 | 一种小鼠α干扰素的时间分辨荧光免疫分析试剂盒及其检测方法 |
JP6466904B2 (ja) | 2013-03-15 | 2019-02-06 | ヤンセン バイオテツク,インコーポレーテツド | インターフェロンアルファ及びオメガ抗体アンタゴニスト |
CN103484434A (zh) * | 2013-06-28 | 2014-01-01 | 朱艮苗 | 杂交瘤细胞株及其应用 |
WO2015001013A2 (en) | 2013-07-03 | 2015-01-08 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
CN103592441B (zh) * | 2013-10-29 | 2015-06-17 | 王明丽 | 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法 |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
WO2016112497A1 (zh) * | 2015-01-13 | 2016-07-21 | 中国人民解放军军事医学科学院生物工程研究所 | 人源抗人α干扰素抗体及其应用 |
JP6835835B2 (ja) * | 2015-10-15 | 2021-02-24 | バイオコン・リミテッドBiocon Limited | ヒト血清中の組み換えヒトインシュリンに対する中和抗体を検出するための方法 |
US10279565B2 (en) | 2016-02-11 | 2019-05-07 | Guardian Glass, LLC | Vacuum insulating glass window unit including edge seal and/or method of making the same |
CN109790526A (zh) | 2016-07-01 | 2019-05-21 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
KR20200039778A (ko) | 2017-08-22 | 2020-04-16 | 사나바이오, 엘엘씨 | 가용성 인터페론 수용체 및 그의 용도 |
AU2020222262B2 (en) | 2019-02-15 | 2024-06-20 | Astrazeneca Ab | Type I interferon-mediated disorders |
JP2022527542A (ja) * | 2019-04-04 | 2022-06-02 | ヤンセン バイオテツク,インコーポレーテツド | 抗IFN-α/ω抗体の投与方法 |
CN116063487B (zh) * | 2022-10-19 | 2023-08-29 | 武汉爱博泰克生物科技有限公司 | 抗人干扰素α2的兔单克隆抗体及其应用 |
Family Cites Families (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE283154C (sl) | ||||
DE279548C (sl) | ||||
DE279547C (sl) | ||||
DE279317C (sl) | ||||
DD265291A (sl) | ||||
DE277087C (sl) | ||||
DE254593C (sl) | ||||
DE279546C (sl) | ||||
DE265291C (sl) | ||||
DE279266C (sl) | ||||
GB1160544A (en) | 1965-06-10 | 1969-08-06 | Reginald Frank Milton | Method and apparatus for Preventing Condensation |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IN150740B (sl) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
FI77877C (fi) | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Foerfarande foer framstaellning och rening av human le-formig interferonprotein. |
US6410697B1 (en) | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4423147A (en) | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
EP0050129B1 (en) | 1980-04-11 | 1992-03-18 | Celltech Limited | Monoclonal antibody |
US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
EP0064063B1 (en) | 1980-11-07 | 1985-09-11 | Celltech Limited | Assay for interferon |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
AU561649B2 (en) | 1981-02-27 | 1987-05-14 | F. Hoffmann-La Roche Ag | Antibodies to proteins |
US4824432A (en) | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
DE3211263A1 (de) | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
WO1983000693A1 (en) | 1981-08-14 | 1983-03-03 | Berg, Kurt, Frimann | SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES |
JPS5835124A (ja) | 1981-08-24 | 1983-03-01 | Otsuka Pharmaceut Co Ltd | 抗体の製造法 |
JPS5835122A (ja) | 1981-08-24 | 1983-03-01 | Otsuka Pharmaceut Co Ltd | 抗原の製造法 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
JPS58225028A (ja) | 1982-06-25 | 1983-12-27 | Otsuka Pharmaceut Co Ltd | ヒトα型インターフェロン抗体 |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
WO1984003106A1 (en) | 1983-02-04 | 1984-08-16 | Wadley Inst Of Molecular Medic | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
GB8322310D0 (en) | 1983-08-18 | 1983-09-21 | Fujisawa Pharmaceutical Co | Monoclonal antibodies |
GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
FR2560212B1 (fr) | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
JPS6113156A (ja) | 1984-06-28 | 1986-01-21 | Sumitomo Chem Co Ltd | ヒトインタ−フエロン−αの定量用試薬及び定量法 |
JPS6172722A (ja) | 1984-09-19 | 1986-04-14 | Nippon Sekijiyuujishiya | 抗インタ−フエロン単クロ−ン抗体及び同抗体を用いたヒト白血球インタ−フエロンの精製法 |
DD231007A1 (de) | 1984-10-01 | 1985-12-18 | Adw Ddr | Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes interferon-alpha (huifn) |
JPS6199828A (ja) | 1984-10-22 | 1986-05-17 | Sumitomo Electric Ind Ltd | 微小温度測定装置 |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JPS61225136A (ja) | 1985-03-28 | 1986-10-06 | Yamasa Shoyu Co Ltd | マウスインタ−フエロンαに対するモノクロ−ナル抗体 |
US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3685996T2 (de) * | 1985-06-11 | 1993-01-14 | Ciba Geigy Ag | Hybrid-interferone. |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
KR880001757B1 (ko) | 1985-10-02 | 1988-09-12 | 제일제당 주식회사 | 알파 인터페론 정제에 효과가 있는 단일항체의 제조방법 |
US5516515A (en) | 1986-02-05 | 1996-05-14 | Interferon Sciences, Inc. | Separation of alpha interferon receptor proteins and antibodies therefor |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
DD279546A1 (de) | 1986-06-17 | 1990-06-06 | Akad Wissenschaften Ddr | Verfahren zur immunaffinitaetschromatographischen reinigung von human-alpha-interferonen |
GB8615353D0 (en) | 1986-06-24 | 1986-07-30 | Antibioticos Sa | Interferon |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4795477A (en) | 1986-07-16 | 1989-01-03 | Celanese Corporation | Printable polyacetal compositions |
DE3633323A1 (de) | 1986-10-01 | 1988-04-07 | Boehringer Ingelheim Int | Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega |
DD279548A1 (de) | 1986-10-15 | 1990-06-06 | Akad Wissenschaften Ddr | Verfahren zur quantitativen bestimmung von human-interferon-alpha-1 |
DD279547A1 (de) | 1986-10-15 | 1990-06-06 | Akad Wissenschaften Ddr | Immunenzymometrisches bestimmungsverfahren fuer den quantitativen nachweis von human-interferon-alpha-2 |
GB8625480D0 (en) | 1986-10-24 | 1986-11-26 | Thomas J M | Length measuring device |
JPS63142000A (ja) | 1986-12-04 | 1988-06-14 | Meiji Seika Kaisha Ltd | モノクロナ−ル抗体 |
DD254593A1 (de) | 1986-12-15 | 1988-03-02 | Adw Ddr | Verfahren zur herstellung monoklonaler antikoerper gegen humanes interferon-alpha |
KR920000051B1 (ko) | 1987-01-12 | 1992-01-06 | 제일제당 주식회사 | 재조합 α-인터페론의 정제방법 |
IE81149B1 (en) | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
EP0397687B1 (en) | 1987-12-21 | 1994-05-11 | The University Of Toledo | Agrobacterium mediated transformation of germinating plant seeds |
EP0332084B1 (en) | 1988-03-05 | 1993-06-23 | Ohi Seisakusho Co., Ltd. | Air spoiler retracting device |
CS267392B1 (en) | 1988-07-22 | 1990-02-12 | Kontsek Peter | Mouse lymphocytar hybridom vu ifn al 6 |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US6747131B1 (en) | 1988-10-28 | 2004-06-08 | Pestka Biomedical Laboratories, Inc. | Phosphorylated fusion proteins |
US5986061A (en) | 1988-10-28 | 1999-11-16 | Pbl Biomedical Laboratories | Phosphorylated fusion proteins |
DD277087A1 (de) | 1988-11-21 | 1990-03-21 | Adw Ddr | Verfahren zur gewinnung von neutralisierenden monoklonalen antikoerpern gegen humanes interferon-alpha |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5073491A (en) | 1988-12-23 | 1991-12-17 | Hoffman-La Roche Inc. | Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DD279317A1 (de) | 1989-01-02 | 1990-05-30 | Akad Wissenschaften Ddr | Testbesteck zur immunenzymometrischen bestimmung von human-interferon-alpha-1 |
DD279266A1 (de) | 1989-01-02 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes interferon-alpha-1 (huifn-alpha-1) |
DD283154A5 (de) | 1989-05-10 | 1990-10-03 | Adw Ddr | Verfahren zur herstellung monoklonaler antikoerper gegen humanes interferon-alpha 1 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
JP2888443B2 (ja) | 1989-12-07 | 1999-05-10 | 日本ケミカルリサーチ株式会社 | ヒト白血球インターフェロン亜種の抗体の製造法及び測定法 |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2657881A1 (fr) | 1990-02-05 | 1991-08-09 | Europ Biotechnologie Lab | Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides. |
JP2808794B2 (ja) | 1990-02-22 | 1998-10-08 | ソニー株式会社 | 両面光ディスク |
SU1756349A1 (ru) | 1990-03-23 | 1992-08-23 | Институт Микробиологии И Вирусологии Им.Д.К.Заболотного | Штамм бактерий СоRYNевастеRIUм SереDоNIсUм - продуцент полисахарида, индуцирующего образование интерферона |
KR0149181B1 (ko) | 1990-06-29 | 1998-08-17 | 데이비드 알, 맥지 | 형질전환된 미생물에 의한 멜라닌의 제조방법 |
JPH0477431A (ja) | 1990-07-19 | 1992-03-11 | Kanebo Ltd | インターフェロン誘起剤 |
US5071762A (en) | 1990-08-13 | 1991-12-10 | Phillips Petroleum Company | Enhancing the flavor of protein products derived from microorganisms |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CS276203B6 (en) | 1990-10-22 | 1992-04-15 | Virologicky Ustav Sav | Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2 |
CS512290A3 (en) | 1990-10-22 | 1992-04-15 | Virologicky Ustav Sav | Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
JPH07503851A (ja) | 1992-02-10 | 1995-04-27 | インターフェロン・サイエンシズ、インコーポレイテッド | 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法 |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
DE4216200A1 (de) | 1992-05-15 | 1993-11-18 | Max Delbrueck Centrum | Verfahren zur Herstellung von monoklonalen Antikörpern gegen humanes Interferon-alpha-2 |
JPH0650971A (ja) | 1992-05-27 | 1994-02-25 | Takeda Chem Ind Ltd | ヒトインターフェロンαの免疫学的測定法およびその試薬 |
CZ4038U1 (cs) | 1992-08-28 | 1995-10-30 | Miroslav Šafek | Elektrický soklový konvektor |
IL108584A (en) * | 1994-02-07 | 2008-03-20 | Yeda Res & Dev | Cloning of the interferon-binding protein ALPHA / BETA |
WO1995013539A1 (fr) | 1992-09-30 | 1995-05-18 | Daiichi Pure Chemicals Co., Ltd. | Methode de dosage d'anticorps anti-interferon et reactif utilise dans ce dernier |
US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
US5626843A (en) | 1993-02-26 | 1997-05-06 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor |
CA2164811A1 (en) | 1993-06-11 | 1994-12-22 | Sidney Pestka | Super proteins including interferons and interleukins |
US6299870B1 (en) | 1993-06-11 | 2001-10-09 | Pbl Biomedical Laboratories | Mutant human interferons |
US6001589A (en) | 1993-06-11 | 1999-12-14 | Pbl Biomedical Laboratories, Inc. | Method of identifying proteins modified by disease states related thereto |
ATE163231T1 (de) | 1993-11-23 | 1998-02-15 | Genentech Inc | Kinaserezeptoraktivierungstest |
EP0741577B1 (en) * | 1994-03-07 | 2002-11-06 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE | The use of interferon subtype alpha 8 in the preparation of medicaments to treat viral infections of the liver |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AU2466895A (en) * | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US7285526B2 (en) | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
US5780027A (en) | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6433145B1 (en) | 1998-07-21 | 2002-08-13 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
KR100483494B1 (ko) * | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
JP5456222B2 (ja) | 1998-12-23 | 2014-03-26 | ジェネンテック, インコーポレイテッド | Il−1関連ポリペプチド |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
US6312924B1 (en) | 1999-03-18 | 2001-11-06 | Zymogenetics, Inc. | Murine interferon-α |
GB0001712D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
WO2002006329A2 (en) | 2000-07-18 | 2002-01-24 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
EP2292652A2 (en) | 2000-11-03 | 2011-03-09 | Pestka Biomedical Laboratories, Inc. | Interferons uses and compositions related thereto |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
FR2821625B1 (fr) | 2001-03-01 | 2003-05-16 | Genodyssee | Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
FR2822845B1 (fr) | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
US6580843B2 (en) | 2001-04-05 | 2003-06-17 | Fujitsu Limited | Optical device |
FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
FR2824333B1 (fr) | 2001-05-03 | 2003-08-08 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 |
FR2825102B1 (fr) | 2001-05-23 | 2003-08-29 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'interferon alpha 14 |
FR2825716B1 (fr) | 2001-06-11 | 2004-09-24 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 |
US6860645B2 (en) | 2003-06-26 | 2005-03-01 | Furukawa Electric North America, Inc. | Optical fiber cable connector assembly with strain relief |
US9109133B2 (en) | 2012-04-19 | 2015-08-18 | Seiko Epson Corporation | Ink jet ink and recorded object |
-
2002
- 2002-01-09 US US10/044,896 patent/US7087726B2/en not_active Expired - Lifetime
- 2002-01-29 NZ NZ527338A patent/NZ527338A/en not_active IP Right Cessation
- 2002-01-29 CN CN2010101807062A patent/CN101857636B/zh not_active Expired - Lifetime
- 2002-01-29 PT PT90024043T patent/PT2065467E/pt unknown
- 2002-01-29 SI SI200230973T patent/SI1362105T1/sl unknown
- 2002-01-29 EP EP10180677A patent/EP2301629A3/en not_active Withdrawn
- 2002-01-29 IL IL15717002A patent/IL157170A0/xx unknown
- 2002-01-29 DK DK09002404.3T patent/DK2065467T5/da active
- 2002-01-29 EP EP09002404.3A patent/EP2065467B9/en not_active Expired - Lifetime
- 2002-01-29 EP EP10007173.7A patent/EP2292301B1/en not_active Expired - Lifetime
- 2002-01-29 CA CA2437161A patent/CA2437161C/en not_active Expired - Lifetime
- 2002-01-29 AU AU2002306432A patent/AU2002306432B2/en not_active Expired
- 2002-01-29 KR KR1020037011067A patent/KR100940968B1/ko active IP Right Grant
- 2002-01-29 JP JP2002566354A patent/JP4384853B2/ja not_active Expired - Lifetime
- 2002-01-29 EP EP10010649A patent/EP2305714A3/en not_active Withdrawn
- 2002-01-29 PT PT02742463T patent/PT1362105E/pt unknown
- 2002-01-29 ES ES10007173.7T patent/ES2461148T3/es not_active Expired - Lifetime
- 2002-01-29 ES ES09002404.3T patent/ES2436787T3/es not_active Expired - Lifetime
- 2002-01-29 ES ES02742463T patent/ES2378062T3/es not_active Expired - Lifetime
- 2002-01-29 EP EP02742463A patent/EP1362105B1/en not_active Expired - Lifetime
- 2002-01-29 CN CNA028053516A patent/CN1492930A/zh not_active Withdrawn
- 2002-01-29 AT AT02742463T patent/ATE534739T1/de active
- 2002-01-29 WO PCT/US2002/002709 patent/WO2002066649A2/en active Application Filing
- 2002-01-29 KR KR1020107016453A patent/KR101154643B1/ko active IP Right Grant
- 2002-01-29 KR KR1020117011680A patent/KR101413907B1/ko active IP Right Grant
- 2002-01-29 SI SI200231038T patent/SI2065467T1/sl unknown
- 2002-01-29 KR KR1020097020269A patent/KR20090107095A/ko not_active Application Discontinuation
- 2002-01-29 RU RU2003128365/13A patent/RU2314317C2/ru active
- 2002-01-29 CN CN2012103448646A patent/CN102993303A/zh active Pending
- 2002-01-29 KR KR1020127030564A patent/KR20120137512A/ko not_active Application Discontinuation
- 2002-01-29 DK DK02742463.9T patent/DK1362105T3/da active
- 2002-01-29 MX MXPA03007529A patent/MXPA03007529A/es active IP Right Grant
-
2003
- 2003-07-30 IL IL157170A patent/IL157170A/en unknown
-
2006
- 2006-03-10 US US11/373,527 patent/US7582445B2/en not_active Expired - Lifetime
- 2006-06-12 US US11/423,588 patent/US7910707B2/en active Active
- 2006-12-14 AU AU2006252117A patent/AU2006252117A1/en not_active Abandoned
-
2008
- 2008-11-21 JP JP2008298277A patent/JP5349018B2/ja not_active Expired - Lifetime
-
2010
- 2010-09-15 US US12/882,980 patent/US20110268727A1/en not_active Abandoned
-
2011
- 2011-02-18 AU AU2011200707A patent/AU2011200707B2/en not_active Expired
- 2011-02-24 US US13/034,551 patent/US8349331B2/en not_active Expired - Lifetime
- 2011-04-11 HK HK11103609.4A patent/HK1149567A1/xx not_active IP Right Cessation
- 2011-08-04 HK HK11108154.2A patent/HK1153967A1/xx not_active IP Right Cessation
-
2012
- 2012-01-30 CY CY20121100101T patent/CY1112385T1/el unknown
- 2012-05-21 US US13/476,878 patent/US8557967B2/en not_active Expired - Lifetime
- 2012-09-04 JP JP2012194560A patent/JP2012245008A/ja active Pending
- 2012-12-03 US US13/692,952 patent/US20130084295A1/en not_active Abandoned
-
2013
- 2013-07-31 US US13/956,266 patent/US20130309236A1/en not_active Abandoned
- 2013-12-19 CY CY20131101150T patent/CY1114901T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2065467T1 (sl) | Protitelesa proti interferonu alfa | |
WO2003057006A3 (en) | Use of antibodies against the muc18 antigen | |
WO2005115437A3 (en) | Methods for affecting body composition | |
SI1814878T1 (sl) | Spojine spiro-2,4-pirimidindiamina in njihova uporaba | |
EP2292661A3 (en) | Interleukin-10 antibodies | |
EP1571548A3 (en) | Hosted application as a designer in an integrated development environment | |
DE602006002265D1 (de) | Wärmeleitfähige silikonkautschukzusammensetzung | |
WO2006072068A3 (en) | Dynamic splint assembly | |
TW200634085A (en) | Elastomer composition and molded body | |
WO2004069152A3 (en) | Δ4,5 glycuronidase and uses thereof | |
WO2005069854A3 (en) | Methods and materials relating to novel c1q domain-containing polypeptides and polynucleotides | |
WO2005117979A3 (en) | Use of il-17 in the treatment of fertility-related disorders | |
AU2003253595A8 (en) | Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof | |
WO2003058353A3 (en) | Watch light | |
WO2005006714A3 (en) | Carabiner communication device | |
AU2004208906A8 (en) | Suit for use in or on water | |
EP1695968A4 (en) | GLUCAGON PEPTIDE 1 RECEPTOR AGONISTS, THEIR PREPARATION AND THE USE THEREOF | |
EP2292666A3 (en) | Neoplasm specific antibodies and uses thereof | |
WO2005062893A3 (en) | Anti-cd52 antibody treatment for diabetes | |
CA2391497A1 (en) | Use of 5ht3 agonists for relaxing the fundus | |
Cantera | Hair-saving unhairing process. Part 2. Immunization phenomenon | |
Barbosa | (Cognitive Development)=(Biology+ Social Context): Is the Whole the Sum of Parts? | |
Allen | Dermot Gleeson. | |
TW200608274A (en) | Computer mouse being able to place picture | |
Manukhin | On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya |